MC
BMY.RT

Muhlenkamp & Co’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Muhlenkamp & Co’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-69,403
Closed -$48K – 38
2020
Q4 		$48K Sell
69,403
-593
-0.8% -$1.26K 0.02% 37
2020
Q3 		$157K Sell
69,996
-125
-0.2% -$357 0.08% 32
2020
Q2 		$251K Buy
+70,121
New +$253K 0.13% 31
2019
Q4 		$213K Buy
+70,665
New +$184K 0.09% 36

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Muhlenkamp & Co's BMY.RT Position: Q1 2021 in Review

Muhlenkamp & Co sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 69,403 shares — an estimated $48K sold.

Muhlenkamp & Co first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $251K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Muhlenkamp & Co reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Muhlenkamp & Co sold 69,403 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $48K.
  • Muhlenkamp & Co first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • Muhlenkamp & Co's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $251K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Muhlenkamp & Co's 13F filing for Q1 2021, filed 18 Aug 2021.